Subclinical Changes in Type 2 Diabetes Patients with Heart Failure Stage A and B Treated with Oral Semaglutide

Subclinical Changes in Type 2 Diabetes Patients with Heart Failure Stage A and B Treated with Oral Semaglutide

<i>Background and Objectives</i>: Heart failure (HF) among patients with type 2 diabetes (T2DM) is linked to significant morbidity and mortality, despite the increased availability of new drug therapy. This study aims to investigate subclinical changes in patients with HF stage A (at ris...

Full description

Saved in:
Bibliographic Details
Main Authors: Larissa Dăniluc, Adina Braha, Oana Elena Sandu, Carina Bogdan, Loredana Suhov, Lina Haj Ali, Alexandra-Iulia Lazăr-Höcher, Alexandra Sima, Adrian Apostol, Mihaela Viviana Ivan
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Medicina
Subjects:
speckle-tracking echocardiography
GLP-1 receptor agonists
visceral adiposity
metabolic control
Online Access:https://www.mdpi.com/1648-9144/61/4/567
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:<i>Background and Objectives</i>: Heart failure (HF) among patients with type 2 diabetes (T2DM) is linked to significant morbidity and mortality, despite the increased availability of new drug therapy. This study aims to investigate subclinical changes in patients with HF stage A (at risk for HF) and B (Pre-HF) and T2DM treated with oral semaglutide. <i>Materials and Methods</i>: In a prospective, observational, single-center study, 50 T2DM patients were assessed at baseline and one-year follow-up for changes in spectral Doppler, tissue Doppler, and speckle-tracking (2DST) and metabolic parameters. <i>Results</i>: Correlation and regression analyses identified predictors of Δ GLS. In correlation analysis, Δ GLS showed a negative correlation with Δ VAI (rho = −0.3, <i>p</i> = 0.02), Δ LAP (rho = −0.3, <i>p</i> = 0.04), Δ FPG (rho = −0.3, <i>p</i> = 0.009), Δ TG (rho = −0.4, <i>p</i> = 0.004), and Δ TyG (rho = −0.3, <i>p</i> = 0.02). In linear stepwise regression analysis, the most accurate model, with a <i>p</i>-value < 0.001, was M<sub>3</sub>, explaining 70% of the variance in Δ GLS (adjusted R<sup>2</sup> = 0.7); this model included Δ FPG (beta −0.4, <i>p</i> = 0.001), Δ CRR (beta −1.3, <i>p</i> < 0.001), and Δ LDLc (beta 0.6, <i>p</i> = 0.01). <i>Conclusions:</i> These findings show that improved subclinical left ventricular systolic dysfunction is associated with improved glycemic control, visceral adiposity, and reduced insulin resistance, respectively, with improved lipid profiling.
ISSN:1010-660X
1648-9144

Similar Items